AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Global Amnesia Clinical Trials, H2 2018 Review by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status - ResearchAndMarkets.com

February 26, 2019

DUBLIN--(BUSINESS WIRE)--Feb 26, 2019--The “Amnesia Global Clinical Trials Review, H2, 2018” clinical trials has been added to ResearchAndMarkets.com’s offering.

“Amnesia Global Clinical Trials Review, H2, 2018” provides an overview of Amnesia clinical trials scenario. This report provides top line data relating to the clinical trials on Amnesia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). These reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Key Topics Covered:

  1. List of Tables
  2. List of Figures
  3. Report Guidance
  4. Clinical Trials Report Coverage
  5. Clinical Trials by Region
  6. Clinical Trials and Average Enrollment by Country
  7. Clinical Trials by G7 Countries: Proportion of Amnesia to Central Nervous System Clinical Trials
  8. Clinical Trials by Phase in G7 Countries
  9. Clinical Trials in G7 Countries by Trial Status
  10. Clinical Trials by E7 Countries: Proportion of Amnesia to Central Nervous System Clinical Trials
  11. Clinical Trials by Phase in E7 Countries
  12. Clinical Trials in E7 Countries by Trial Status
  13. Clinical Trials by Phase
  14. In Progress Trials by Phase
  15. Clinical Trials by Trial Status
  16. Clinical Trials by End Point Status
  17. Subjects Recruited Over a Period of Time
  18. Clinical Trials by Sponsor Type
  19. Prominent Sponsors
  20. Top Companies Participating in Amnesia Therapeutics Clinical Trials
  21. Prominent Drugs
  22. Clinical Trial Profile Snapshots
  23. Appendix

Companies Mentioned

  • Yichang Sanxia Pharmaceutical Co Ltd
  • YiChang Humanwell Pharmaceutical Co Ltd
  • Worldwide Clinical Trials Holdings Inc
  • Shandong Wohua Pharmaceutical Co Ltd
  • QR Pharma Inc
  • Nestle Health Science SA
  • Merck & Co Inc
  • Mars Inc
  • Kyowa Hakko Europe GmbH
  • AstraZeneca Plc

For more information about this clinical trials report visit https://www.researchandmarkets.com/research/zsmt4v/global_amnesia?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190226005594/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Clinical Trials

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/26/2019 06:55 AM/DISC: 02/26/2019 06:55 AM

http://www.businesswire.com/news/home/20190226005594/en